Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

MoonLake Immunotherapeutics (MLTX) Non Operating Income (2021 - 2023)

MoonLake Immunotherapeutics' Non Operating Income history spans 3 years, with the latest figure at $1.4 million for Q3 2023.

  • Quarterly Non Operating Income rose 3587.69% to $1.4 million in Q3 2023 from the year-ago period, while the trailing twelve-month figure was $3.2 million through Sep 2023, up 999.27% year-over-year, with the annual reading at $591732.0 for FY2022, 2036.91% up from the prior year.
  • Non Operating Income came in at $1.4 million for Q3 2023, up from $842652.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $1.4 million in Q3 2023 to a low of -$61848.0 in Q4 2021.
  • The 3-year median for Non Operating Income is $69506.0 (2022), against an average of $315966.8.
  • Year-over-year, Non Operating Income surged 6584.92% in 2022 and then soared 243.76% in 2023.
  • MoonLake Immunotherapeutics' Non Operating Income stood at -$61848.0 in 2021, then skyrocketed by 487.25% to $239505.0 in 2022, then skyrocketed by 478.82% to $1.4 million in 2023.
  • Per Business Quant, the three most recent readings for MLTX's Non Operating Income are $1.4 million (Q3 2023), $842652.0 (Q2 2023), and $723589.0 (Q1 2023).